Results 41 to 50 of about 7,548 (263)
Metabolites, 2021 Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or ...
Shinje Moon +6 more
doaj +1 more source
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
Indian Journal of Endocrinology and Metabolism, 2016 Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while ...
Sanjay Kalra +6 more
doaj +1 more source
BMC Endocrine Disorders, 2019 Background This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.
Monika Russel-Szymczyk +3 more
doaj +1 more source
Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes
Endocrine and Metabolic Science, 2021 Introduction: Glycemic control is important in renal transplant receptions with diabetes. In the early post-transplant period, recovering renal function and concomitant steroids and immunosuppressants increase the risk of dysglycemia which adversely ...
Debmalya Sanyal +2 more
doaj +1 more source
Effect of insulin glargine on cardiovascular risk analysed by mean HRV [PDF]
, 2019 Type 2 diabetes mellitus is an insidious disease that is increasingly present in geriatric population [1]. The greatest difficulty is represented by glycaemic control in geriatric patients often not very compliant with diet therapy and drug therapy.
Apicella, G. +5 more
core +1 more source
Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. [PDF]
, 2015 INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a treatment strategy for type 1 diabetes. Transition from multiple daily injection therapy (MDI; including basal-bolus regimens) to CSII is based on ...
Hovorka, R, Mohd-Thabit, HA
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims This post hoc analysis assessed efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec (icodec) versus once‐daily (OD) basal insulin comparators across different baseline glycated haemoglobin (HbA1c), body mass index (BMI) and type 2 diabetes (T2D) duration subgroups using data from five phase 3a trials of icodec in adults with
Alice Y. Y. Cheng +5 more
wiley +1 more source
Alʹmanah Kliničeskoj Mediciny, 2016 Background: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM).
M. F. Kalashnikova +6 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský +14 more
wiley +1 more source
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
Indian Journal of Endocrinology and Metabolism, 2015 Over the past few decades, continuous progress has been made in the development of insulin therapy. Basal insulins were developed around 60 years ago. However, existing basal insulins were found to have limitations. An ideal basal insulin should have the
Sanjay Kalra
doaj +1 more source